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Axillary lymph node involvement is an important prognostic factor for breast cancer survival but is confounded by the number
of nodes examined. We compare the performance of the log odds prognostic index (Lpi), using a ratio of the positive versus
negative lymph nodes, with the Nottingham Prognostic Index (NPI) for short-term breast cancer speciﬁc disease free survival. A
total of 1818 operable breast cancer patients treated in the University Hospital of Leuven between 2000 and 2005 were included.
The performance of the NPI and Lpi were compared on two levels: calibration and discrimination. The latter was evaluated using
the concordance index (cindex), the number of patients in the extreme groups, and diﬀerence in event rates between these. The
NPI had a signiﬁcant higher cindex, but a signiﬁcant lower percentage of patients in the extreme risk groups. After updating both
indices, no signiﬁcant diﬀerences between NPI and Lpi were noted.
1.Introduction
In women with an operable breast cancer, the lymph node
status is amongst the most important prognostic parameters
for disease free survival (DFS). An operable breast cancer
patient was deﬁned as “any consecutive patient with an
invasivebreastcancerwithoutacontraindicationforprimary
surgery”. This excludes patients with metastatic disease and
those previously treated for breast cancer such as those
receiving neoadjuvant systemic treatment. A positive axillary
lymph node status is associated with a clear increase in
risk of recurrence and mortality. Moreover, patients with
at least four positive lymph nodes have a worse prognosis
compared with those with three or less positive nodes [1].
Examination of axillary lymph nodes for tumor involvement
can be performed by axillary lymph node dissection or
sentinel lymph node biopsy [2]. Sentinel lymph node biopsy
enables an accurate nodal staging by examination of one or a
few sentinel lymph nodes, while obviating invasive surgery
of axillary dissection [3]. In case the sentinel lymph node
is positive, a complete axillary lymph node dissection is
performed [4]. However, guidelines deﬁning the minimum
number of lymph nodes to examine in axillary lymph
node dissection and/or sentinel lymph node biopsy are not
available. As the likelihood of ﬁnding positive nodes in the
axilla increases with the number of nodes removed during
axillary lymph node dissection an increasing number of
studies is examining the prognostic value of the nodal ratio,
whichwerenicelyreviewedbyWoodwardandcoworkers[5].
Furthermore, the established Nottingham Prognostic
Index (NPI) [6]i sp u tu n d e rd e b a t ea si tt a k e so n l y
the number of positive lymph nodes into consideration.
Vinh-Hung and colleagues introduced a ratio-based nodal
prognostic index based on the empirical log odds of nodal
involvement [7, 8]. Similar to the NPI, this log odds
prognostic index (Lpi) is computed based on the tumor
size, histological grade, and axillary nodal involvement. The
latter considering the number of negative nodes besides the2 Pathology Research International
number of positive lymph nodes. Using the Surveillance,
Epidemiology and End Results (SEER release 2005, n =
7526) public database, they compared the established NPI
with the alternative Lpi prognostic index. They reported a
better prognostic separation with regard to overall survival
as well as breast cancer speciﬁc survival between risk groups
when deﬁned by the Lpi [7]. This study aimed at evaluating
the prognostic value of Lpi in a dataset of 1818 operable
breast cancer patients from our institution.
2.MaterialsandMethods
A total of 2,024 operable female breast cancer patients who
were treated in the University Hospitals of Leuven between
2000 and 2005 and underwent lymph node dissection
were available for this study. Only patients without prior
pathologic sentinel lymph node evaluation (n = 1,838) were
included. After exclusion of 20 patients lacking information
onsize,grade,orlymphnodestatus,1,818patientsremained
for analysis. None of these patients received neoadjuvant
therapy. Tumor characteristics and lymph node status were
retrieved from pathology reports and together with clinical
data gathered in our central breast cancer database. The
lymph node status was deﬁned according to AJCC criteria.
Isolatedtumor cellswere consideredas lymph node negative.
Surgical treatment consisted in wide local excision plus
axillary dissection followed by whole breast radiotherapy
plus a boost on the tumour bed, or modiﬁed radical mas-
tectomy when breast-conserving surgery was not indicated.
Chest wall RT following mastectomy was given to patients
with T3 or T4 tumors, with positive lymph nodes or with
positive tumour section margins. Irradiation to the internal
mammary chain was performed only in cases of axillary
lymph node involvement or medial tumour sites. Endocrine
therapy (HT) was prescribed if the expression ER and/or PR
were present. Although tamoxifen 20mg/day for ﬁve years
was the standard HT, many postmenopausal women also
received an oral aromatase-inhibitor for a period of ﬁve
years. Anthracycline-based chemotherapy (CT) was given
if patients were classiﬁed as intermediate or high risk for
relapse but endocrine sensitivity, NPI, and age at diagnosis
were also important when deciding upon systemic adjuvant
therapy.
Patients were followed until June 2009 for cancer
recurrence through clinical records or through contact with
the general practitioner by phone. Median follow-up time
was 5.92 year (interquartile range (IQR): 4.33–7.12 year).
During the follow-up period, 67 patients developed local
recurrenceand193developeddistantmetastasis.Forpatients
with bilateral cancer at ﬁrst diagnosis, the worse NPI and
concordant Lpi value were taken into account.
NPI and Lpi were calculated using tumor size, histo-
logical grade, number of positive and/or negative lymph
nodes. Tumor size was deﬁned as the maximum diameter
of the tumor in cm. Histological grading of tumors was
performed according to the Ellis and Elston system [9].
The NPI was computed as 0,2xtumor size (cm) + grade(1–
3) + nodal score. The nodal score was deﬁned (1) when
n = 2024
lymph node dissection
n = 1838
no sentinel nodes
n = 1818
complete cases
n = 909
training set
Obtain predicted survival
Update Lpi and NPI
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Tables 1–3, Figure 2
n = 909
test set
Calibration
Figure 3
KM survival curves
Discrimination
Calibration
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Figure 1: Flow chart: from the 2024 patients treated in our
institution, 1,818 were eligible for this study. This cohort was used
to summarize patient characteristics, Kaplan-Meier survival curves,
and univariable survival analysis. The discriminating ability of the
NPI and Lpi were compared on this cohort. Calibration of both
models was checked on the test set (a random half of the data),
after obtaining the predicted survival curves on the training set.
The same training set was used to update both models. Kaplan-
Meier curves, discrimination, and calibration ability of the updated
models were calculated on the test set.
no nodal involvement was present, (2) when ≤3p o s i t i v e
lymph nodes, and (3) when >3 positive lymph nodes were
present. The Lpi was computed using an equation published
in [8]: size(cm) +1 if grade > 2(0 otherwise)+log((npos+
0.5)/(nneg+0.5)), where npos, en, and nneg are the number
of positive and negative nodes, respectively.
3.StatisticalAnalyses
Patients were followed from the date of surgery until
a breast cancer-related event (locoregional recurrence or
distant metastasis) occurred. In case no event was observed
within the study time, patients were censored at the last
date of followup. This time will be denoted as the disease-
free survival time (DFS). Survival curves are calculated by
means of the Kaplan-Meier (KM) method. The logrank
test is used to test for statistical signiﬁcant diﬀerences in
survival. All variables used in both prognostic models were
used in a univariate Cox model to check their relevance on
our dataset. The prognostic models are validated on two
levels: discrimination and calibration. The discrimination
ability is summarized in the concordance index (cindex)
[10]. For clinical practice, a model categorizing patients in
the most extreme risk groups is preferred [11]. Therefore,Pathology Research International 3
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Figure 2:Kaplan-Meiersurvivalcurvesforriskgroupsaccordingto
NPI (black lines) and Lpi (grey lines). The solid, dashed, and dot-
dashed lines represent the low, intermediate, and high-risk group,
respectively. The survival curves for both low-risk groups and for
both high risk groups do not diﬀer signiﬁcantly. However, since the
Lpi classiﬁes signiﬁcantly more patients into the low-risk group, the
survival for Lpi intermediate risk patients is signiﬁcantly lower than
for NPI intermediate patients.
the percentage of patients in the low and high risk groups
are calculated (EXT%). Additionally, the diﬀerence in event
rates between high and low risk groups are reported (EvR).
The event rate is calculated as the number of events divided
by the total followup of all patients in the group. The
inverse of the event rate is interpreted as the number of
years one has to wait before an event is expected to occur.
Bootstrap adjusted 95% conﬁdence limits were calculated
on all validation measures, using 1000 bootstrap samples
of the dataset. Calibration plots are made to check whether
the predicted survival chance corresponds with the true
survival. Therefore, the test data were divided into ﬁve
groups according to the value of the NPI (Lpi). For each
group, the observed survival as calculated by the Kaplan-
Meier estimator at 5 years and the median predicted survival
at 5 years are calculated. The calibration plot summarizes
the results. However, since the NPI was developed on
a dataset containing 351 operable breast cancer patients
from 1976–1981 and the Lpi on the SEER 2005 dataset
containing 7526 patients from 1988–2004, it is reasonable
to assume that these patient populations diﬀer from ours.
Not only is the treatment continuously changing, but the
number of examined lymph nodes may diﬀer from centre
to center. Therefore, our data was randomly divided in a
training and test set (both containing 50% of the data). The
model predicted survival was obtained from the training set.
Calibration was then checked on the test set.
Steyerberg [12] proposed model updating in cases where
it is expected that patient populations between training and
test sets will diﬀer. Populations can diﬀer due to temporal
or spatial diﬀerences. To overcome these transportability
p r o b l e m s ,t h eN P Ia n dL p iw e r eu p d a t e do nh a l fo fo u r
dataset (training set, see above) and validated on the
remaining part (test set). The models were updated by
model revision [12], which involves a re-estimation of the
coeﬃcients. As in [6], the updated prognostic indices are
built from the resulting Cox proportional hazard regression
model.
To categorize patients into risk groups, 1000 bootstraps
ofthetrainingdatasetwereused.Ineachbootstrapthelower
and higher cutoﬀ values were varied in steps of 0, 2. The
pair leading to the largest cindex on most of the bootstraps
was selected. Figure 1 gives a ﬂow chart of the data and
analysis ﬂow. All statistical analyses were carried out using
the software packages SAS 9.1.3 service pack 4, the level of
signiﬁcance being set at α = 0,05.
4. Results
4.1. Patient Characteristics. The median age at diagnosis was
57 years (IQR 48-67). All patients were treated with local
surgery. The median number of dissected lymph nodes for
all patients was 16 (IQR 12–21). A total of 38% (695/1818)
of patients had lymph node metastasis with on average 4.11
(IQR 1–5) involved nodes. The median follow-up time was
5.92 year (IQR 4.33–7.12 year). Patients’ characteristics are
summarized in Table 1.
4.2. Discrimination and Calibration. Figure 2 illustrates the
KM curves for NPI and Lpi risk groups. The number of
patients in the low, intermediate, and high risk group for
the NPI are 464, 934, 420, and for the Lpi 934, 736, 148,
respectively. Although the Lpi has much more low risk
patients than the NPI, DFS of both groups does not diﬀer
signiﬁcantly (P = .2176). Due to the allocation of patients
to lower risk groups in the Lpi the DFS of the intermediate
Lpi group is signiﬁcantly lower than that for intermediate
NPI patients (P<. 001). As a ﬁrst analysis, the signiﬁcance
of all variables in both the NPI and Lpi is checked in a
univariate Cox model (Table 2). All variables included in
both prognostic indices remain signiﬁcant in our series.
Table 3 summarizes the performance of both models. The
NPI has a signiﬁcantly higher cindex, but a signiﬁcantly
l o w e rE X T % .T h em o d e l sd on o td i ﬀer in the diﬀerence
between high and low risk event rates. Figure 3 shows that
the NPI is better calibrated than the Lpi.
4.3. Model Updating. The major diﬀerence between the NPI
and the Lpi lies in the substitution of staging of the number
of positive lymph nodes by the ratio of positive versus
negative nodes. In [13, 14], it was indicated that the ratio
of positive versus the total number of examined lymph
nodes is a better prognostic than the number of positive
nodes per se. However, the number of examined nodes can
diﬀer between centres, which would result in diﬀerent model
coeﬃcients. Therefore, both models are updated [12] using
a random half of the dataset (training set). The updated4 Pathology Research International
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Figure 3: Calibration plot: (a) NPI, (b) Lpi. The test data are divided into 5 groups according to the value of the NPI (Lpi). For each group,
the observed survival as calculated by the Kaplan-Meier estimator at 5 years and the median predicted survival at 5 years are plotted (circles).
Ideally, the circles should lie on the dashed line. 95% conference intervals on the observed survival probabilities are represented by the
vertical lines. The NPI is better calibrated than the Lpi.
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Figure 4: Calibration plot after updating the models: (a) NPI, (b) Lpi. The test data are divided into 5 groups according to the value of the
NPI (Lpi). For each group, the observed survival as calculated by the Kaplan-Meier estimator at 5 years and the median predicted survival at
5 years are plotted (circles). Ideally, the circles should lie on the dashed line. 95% conference intervals on the observed survival probabilities
are represented by the vertical lines. Both indices are well calibrated.
NPI is built as 0.8xgrade + 0.4xnodal score, where grade
and nodal score are deﬁned as previously. The updated Lpi
is built as 0.9 (if the grade is larger than 2, zero otherwise)
+ 0.4xlog((npos + 0.5)/(nneg + 0.5 ) ) .T h es i z ew a sd r o p p e d
from both formulas since the eﬀect was no longer signiﬁcant
when taken together with the nodal score or lymph node
ratio. Table 4 summarizes the performance of both updated
models. No statistical diﬀerences are noted between both
models. Figure 4 illustrates that both updated models are
well calibrated.
Using 1000 bootstrap samples of the training set, the
optimal cutoﬀs for NPI and Lpi were obtained as {2.85,
3.65} and {−0.90, 0.00},r e s p e c t i v e l y .Figure 5 illustrates the
KM survival estimates for the updated risk groups. Survival
curves for corresponding NPI and Lpi groups did not diﬀer
signiﬁcantly (P>. 25). Comparing the original models with
the updated models the concordance for the NPI was 0.93,
whereas the concordance for the Lpi was 0.77. Since the
updated NPI corresponds that well with the original NPI,
the major diﬀerence is due to the change of the thresholdPathology Research International 5
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Figure 5: Kaplan-Meier survival curves for risks groups according
to the NPI (black lines) and Lpi (grey lines). The solid, dashed,
and dot-dashed lines represent the low, intermediate, and high risk
group, respectively. The survival curves for corresponding NPI and
Lpi groups do not diﬀer signiﬁcantly.
values. For the Lpi, both the updating of the coeﬃcients and
the change in threshold leads to a better model.
5. Discussion
In our institution, the NPI is taken into account to estimate a
patient’s risk for relapse of breast cancer and to decide upon
the modality of systemic therapy. The combined expression
of ER, PR, and HER-2 is also taken into account, not only
for prognostic but also for predictive purposes. This paper
investigated the potential additional beneﬁt of the number
of involved lymph nodes or the lymph node ratio.
Various prognostic factors have been described in breast
cancer of which the axillary lymph node status and NPI
are considered to be the most important ones. However,
a tendency towards assessment of the nodal ratio can be
seen with various studies indicating a better prognostic
stratiﬁcation of patients by nodal ratio than by number of
positive lymph nodes [13–21]. Furthermore, an alternative
nodal prognostic index for the established NPI has been
put forward [8]. In the present study, we retrospectively
reviewed all clinical charts and pathological reports from
1818 operable breast cancer patients which were treated
in our institution between 2000 and 2005. We determined
the NPI and Lpi value of all patients, updated NPI, and
Lpi, categorized patients into risk groups and evaluated the
results with regard to disease-free survival.
In contrast to the report of Vinh-Hung and colleagues,
we did not ﬁnd a signiﬁcant improvement of the Lpi above
the NPI, although we previously conﬁrmed the superiority
of the LNR above the number of positive lymph nodes [14].
Table 1: Patients’ characteristics.
Characteristic No. of Patients
(n = 1818)
%
Age, years
Median 57
Lower-upper quartiles 48–67
Histologic grade
low 242 13.31
intermediate 823 45.27
high 753 41.42
Tumor size, cm
Median 2.3
Lower-upper quartiles 1.5–3.5
No. of lymph nodes removed
Median 16
Lower-upper quartiles 12–21
No. of positive lymph nodes
Median 0
Lower-upper quartiles 0-1
Range 0–42
Pathologic nodal stage (pN)
0 1123 61.77
1–3 456 25.08
> 3 239 13.15
Node ratio
Median 0.04
Lower-upper quartiles 0.03–0.14
Adjuvant treatment
No adjuvant treatment 37 0.02
Radiotherapy 1519 83.55
Chemotherapy 655 36.03
Endocrine Therapy 1430 78.66
After updating both models, this conclusion remained. Since
no signiﬁcant diﬀerences between the Lpi and the NPI are
noted, the NPI is preferred above the Lpi. The former index
islessdependentoncentresinceitonlyincludeswell-deﬁned
variables. The Lpi on the contrary includes the number
of examined lymph nodes which might vary according to
the centre/surgeon. Therefore, Lpi would need updating to
acquire the same performance as the NPI.
We believe this study to be of great value despite its
smaller size in comparison with the study of [8]. First, our
patient population is representative for the overall breast
cancerpopulationwithrespecttothemedianageatdiagnosis
and number of patients in the various NPI risk groups
[22, 23]. Second, all patients in the study were diagnosed and
treated in a single institution by one multidisciplinary team.
However, our study also has its weaknesses such as the lack
of overall survival analyses and a relatively short follow-up
time.6 Pathology Research International
Table 2: Cox univariate analysis of prognostic variables included in
the NPI and Lpi, and NPI and Lpi.
Variable HR 95% CI P-value
Size (cm) 1.081 1.028–1.136 .0023
pN
low versus high 0.527 0.453–0.612 <.0001
pN
intermediate versus high 0.630 0.512–0.775 <.0001
Grade
low versus high 0.432 0.350–0.533 <.0001
Grade
intermediate versus high 0.642 0.559–0.737 <.0001
Lymph node ratio 1.427 1.328–1.533 <.0001
Grade
low and intermediate versus high 2.644 2.057–3.398 <.0001
HR: hazard ratio
pN: pathological nodal status
Table 3: Measures of model performance of NPI and Lpi.
Signiﬁcant better performance is indicated in bold.
measure NPI Lpi
95% CI for the
diﬀerence between NPI
and Lpi
cindex 0.69 0.66 0.01; 0.04
EvR 0.04 0.04 −0.01; 0.02
EXT% 48.6 59.5 −0.14; −0.08
EvR: diﬀerence in event rate in high versus low risk patients
EXT%: percentage of patients classiﬁed into the most extreme risk groups
CI: conﬁdence interval.
Table 4: Measures of model performance of NPI and Lpi, after
updating. Signiﬁcant better performance is indicated in bold.
measure NPI Lpi
95% CI for the
diﬀerence between NPI
and Lpi
cindex 0.69 0.69 −0.02; 0.02
EvR 0.08 0.05 −0.00; 0.05
EXT% 0.66 0.67 −0.04; 0.01
Diﬀerence in event rate in high versus low risk patients
EXT%: percentage of patients classiﬁed into the most extreme risk groups
CI: conﬁdence interval.
6. Conclusion
This study aimed at evaluating the prognostic value of the
Lpiwithrespecttodisease-freesurvival.However,besidesthe
Lpi various other prognostic indices are under investigation
as improvement of the established NPI [22, 24]. Based onthe
results from our study, we can conclude that the Lpi does not
perform better than the NPI.
Conﬂict of Interests
The authors declare no conﬂict of interests.
Acknowledgments
TheauthorsthankProfessorDr.P.Sch¨ oﬀskiforhisconstruc-
tive remarks. This research is supported by Research Coun-
cil KUL: GOA-AMBioRICS, GOA-MaNeT, CoE EF/05/006
Optimization in Engineering (OPTEC); Flemish Govern-
ment: FWO: G.0341.07 (Data Fusion); Belgian Federal
Science Policy Oﬃce IUAP P6/04 (DYSCO, “Dynamical
systems, control, and optimization”, 2007–2011), Vlaamse
Liga tegen Kanker (VLK, Brussel) and the EU Framework
Programme 6 project LSHC-CT-2003-503297 (Cancerde-
gradome project). V. V. Belle is supported by a grant from
the IWT. None of the sponsors had any involvement in the
study.
References
[1] C. L. Carter, C. Allen, and D. E. Henson, “Relation of tumor
size, lymph node status, and survival in 24,740 breast cancer
cases,” Cancer, vol. 63, no. 1, pp. 181–187, 1989.
[2] J.R.BensonandG.Q.dellaRovere,“Managementoftheaxilla
in women with breast cancer,” Lancet Oncology, vol. 8, no. 4,
pp. 331–348, 2007.
[3] H. Mabry and A. E. Giuliano, “Sentinel node mapping for
breast cancer: progress to date and prospects for the future,”
Surgical Oncology Clinics of North America, vol. 16, no. 1, pp.
55–70, 2007.
[ 4 ]G .H .L y m a n ,A .E .G i u l i a n o ,M .R .S o m e r ﬁ e l de ta l . ,“ A m e r i -
can Society of Clinical Oncology guideline recommendations
for sentinel lymph node biopsy in early-stage breast cancer,”
Journal of Clinical Oncology, vol. 23, no. 30, pp. 7703–7720,
2005.
[5] W.A.Woodward,V.Vinh-Hung,N.T.Uenoetal.,“Prognostic
value of nodal ratios in node-positive breast cancer,” Journal of
Clinical Oncology, vol. 24, no. 18, pp. 2910–2916, 2006.
[ 6 ]M .H .G a l e a ,R .W .B l a m e y ,C .E .E l s t o n ,a n dI .O .E l l i s ,“ T h e
Nottinghamprognosticindexinprimarybreastcancer,”Breast
Cancer Research and Treatment, vol. 22, no. 3, pp. 207–219,
1992.
[7] V. Vinh-Hung, C. Verschraegen, D. I. Promish et al., “Ratios of
involved nodes in early breast cancer,” Breast Cancer Research,
vol. 6, no. 6, pp. R680–R688, 2004.
[8] V. Vinh-Hung, P. Tai, G. Storme et al., “A ratio-based nodal
prognosticindexforbreastcancer,”BreastCancerResearchand
Treatment, vol. 100, pp. S220–S221, 2006.
[9] C. W. Elston and I. O. Ellis, “Pathological prognostic factors
in breast cancer. I. The value of histological grade in breast
cancer: experience from a large study with long-term follow-
up,” Histopathology, vol. 19, no. 5, pp. 403–410, 1991.
[10] F. Harrell, K. Lee, R. Caliﬀ,D .P r y o r ,a n dR .R o s a t i ,“ R e g r e s -
sion modeling strategies for improved prognostic prediction,”
Statistics in Medicine, vol. 3, no. 2, pp. 143–152, 1984.
[ 1 1 ]E .G r a f ,C .S c h m o o r ,W .S a u e r b r e i ,a n dM .S c h u m a c h e r ,
“Assessment and comparison of prognostic classiﬁcation
schemes for survival data,” Statistics in Medicine, vol. 18, no.
17-18, pp. 2529–2545, 1999.
[12] E. Steyerberg, Clinical Prediction Models: A Practical Approach
toDevelopment,Validation,andUpdating(StatisticsforBiology
and Health), Springer, New York, NY, USA, 2009.
[13] V. Vinh-Hung, H. M. Verkooijen, G. Fioretta et al., “Lymph
node ratio as an alternative to pN staging in node-positive
breast cancer,” Journal of Clinical Oncology, vol. 27, no. 7, pp.
1062–1068, 2009.Pathology Research International 7
[14] V. van Belle, B. van Calster, H. Wildiers, S. van Huﬀel, and P.
Neven,“Lymphnoderatiobetterpredictsdisease-freesurvival
in node-positive breast cancer than the number of positive
lymph nodes,” Journal of Clinical Oncology, vol. 27, no. 30, pp.
e150–e151, 2009.
[15] M. Hensel, A. Schneeweiss, H. P. Sinn et al., “p53 is the
strongest predictor of survival in high-risk primary breast
cancer patients undergoing high-dose chemotherapy with
autologous blood stem cell support,” International Journal of
Cancer, vol. 100, no. 3, pp. 290–296, 2002.
[16] J. Martinez-Trufero, A. Artal-Cortes, M. Zorrilla et al., “New
distinctive features on the study of prognostic factors in
patients with locally advanced breast cancer (LABC) treated
with neoadjuvant chemotherapy (NAC),” Proceedings of the
American Society of Clinical Oncology, vol. 20, 2001.
[17] L. J. Megale Costa, H. Prado Soares, H. Amaral Gaspar et
al., “Ratio between positive lymph nodes and total dissected
axillarieslymphnodesasanindependentprognosticfactorfor
disease-free survival in patients with breast cancer,” American
Journal of Clinical Oncology, vol. 27, no. 3, pp. 304–306, 2004.
[18] Y. Nieto, P. J. Cagnoni, E. J. Shpall et al., “A predictive
model for relapse in high-risk primary breast cancer patients
treated with high-dose chemotherapy and autologous stem-
cell transplant,” Clinical Cancer Research, vol. 5, no. 11, pp.
3425–3431, 1999.
[ 1 9 ]P .T .T r u o n g ,E .B e r t h e l e t ,J .L e e ,H .A .K a d e r ,a n dI .
A. Olivotto, “The prognostic signiﬁcance of the percentage
of positive/dissected axillary lymph nodes in breast cancer
recurrence and survival in patients with one to three positive
axillarylymphnodes,”Cancer,vol.103,no.10,pp.2006–2014,
2005.
[20] B. C. H. van der Wal, R. M. J. M. Butzelaar, S. van der Meij,
and M. A. Boermeester, “Axillary lymph node ratio and total
number of removed lymph nodes: predictors of survival in
stage I and II breast cancer,” European Journal of Surgical
Oncology, vol. 28, no. 5, pp. 481–489, 2002.
[21] M. Voordeckers, V. Vinh-Hung, J. van de Steene, J. Lamote,
and G. Storme, “The lymph node ratio as prognostic factor in
node-positive breast cancer,” Radiotherapy and Oncology, vol.
70, no. 3, pp. 225–230, 2004.
[22] R.W.Blamey,I.O.Ellis,S.E.Pinderetal.,“Survivalofinvasive
breast cancer according to the Nottingham Prognostic Index
in cases diagnosed in 1990–1999,” European Journal of Cancer,
vol. 43, no. 10, pp. 1548–1555, 2007.
[23] G. D’Eredita’, C. Giardina, M. Martellotta, T. Natale, and F.
Ferrarese, “Prognostic factors in breast cancer: the predictive
value of the Nottingham Prognostic Index in patients with a
long-term follow-up that were treated in a single institution,”
European Journal of Cancer, vol. 37, no. 5, pp. 591–596, 2001.
[24] A. Sidoni, G. Bellezza, A. Cavaliere, R. del Sordo, M. Scheibel,
and E. Bucciarelli, “Prognostic indexes in breast cancer:
comparison of the Nottingham and Adelaide indexes,” Breast,
vol. 13, no. 1, pp. 23–27, 2004.